BALB/c and C57BL/6 mouse strains influence gastric function outcomes with administration of cisplatin and dexamethasone

Abstract

Our aim was to evaluate the effects of cisplatin and dexamethasone alone and combined on gastric contractility and histomorphometry of BALB/c and C57BL/6 mice. BALB/c and C57BL/6 male mice (8-week-old) were randomly separated into: Control; Cisplatin (7.5 mg/Kg); Dexamethasone (2.0 mg/Kg); and Dexamethasone plus Cisplatin (2.0 mg/Kg of dexamethasone 1-hour prior to 7.5 mg/Kg of cisplatin). Drugs were administered intraperitoneally for three days. Body weight and food intake were evaluated on 2nd day. Alternating Current Biosusceptometry technique was employed to measure gastric contractions on 3rd day. Afterward, mice were killed for gastric histomorphometric analysis. Cisplatin decreased food intake and caused bradygastria in BALB/c mice; however, the amplitude of gastric contractions decreased in both BALB/c and C57BL/6. Dexamethasone and cisplatin combined restored the gastric frequency and food intake only in BALB/c, but drug combination reduced the gastric amplitude of contractions in both strains. Dexamethasone alone increased gastric mucosa thickness in C57BL/6 and decreased muscular thickness in BALB/c. In conclusion, the mouse strains presented differences in acute effects of cisplatin and dexamethasone alone and combined on gastric function. This reinforces the importance of choosing the appropriate mouse strain for studying the acute effects of drugs on the gastrointestinal tract.

Keywords:
BALB/c; Bradygastria; C57BL/6; Gastric motility; Stomach

INTRODUCTION

Mice are the species chosen for in vivo drug efficacy/ toxicity studies (Clements et al., 2021). However, it has been observed that mouse strains respond differently to some drugs (Gosselin et al., 2017; Gong et al., 2019), highlighting the impact of the experimental model on data interpretation (Clements et al., 2021). Different mouse strains have distinctive physiological characteristics that impact immune response and also the gastrointestinal (GI) tract (Melgar, Karlsson, Michaëlsson, 2005; Sankoorikal et al., 2006; Miller et al., 2018; Soni et al., 2019; Gama et al., 2020).

Cisplatin (cis-diamminedichloroplatinum [II], Cis) is one of the most widely used chemotherapeutic agents due to its high efficacy and broad-spectrum; however, clinical use is limited by side effects (Qi et al., 2019). Cisplatin is associated with nausea, emesis, mucositis, malabsorption constipation, and diarrhea, which unless treated can lead to dose reductions or discontinuation of chemotherapy (Uranga et al., 2017; Liu et al., 2018; Shahid, Farooqui, Khan, 2018). In addition, cisplatin has been associated with anorexia, delayed gastric emptying, dysrhythmic gastric slow-wave, and morphologic changes in the GI tract (Viana-Cardoso et al., 2011; Uranga et al., 2017). Cisplatin is often used as a drug of choice to study emesis and the effect of anti-emetics in animal models (Shahid, Farooqui, Khan, 2018). Rodents do not have a vomiting reflex but may show nausea-like behaviors such as a reduction in food intake, an increase in non-nutritive substance intake (pica behavior), and a delay in gastric emptying (Perše, 2021). It has been demonstrated that cisplatin-induced pica behavior is affected by the mouse strains (Liu et al., 2005; Yamamoto, Okui, Yamatodani, 2018), although gastrointestinal motility disorders have not been directly assessed.

Antiemetic drug therapy is important to prevent chemotherapy-induced side effects (Yang, Wu, Liaw, 2016). Dopamine D₂ receptor antagonists, serotonin 5-HT₃ receptor antagonists, neurokinin NK₁ receptor antagonists, and corticosteroids are the drugs clinically used to prevent vomiting (Navari, Aapro, 2016). However, recovery of GI function may be an important factor in the treatment of nausea (Sanger, Broad, Andrews, 2013). Dexamethasone is a corticosteroid used in prophylaxis for chemotherapy-induced nausea and vomiting in combination with other drugs (Natale, 2015). Improvements in food intake have also been observed after treatment with dexamethasone (Yamamoto, Okui, Yamatodani, 2018). However, the mechanism by which it prevents chemotherapy-induced nausea and vomiting is still unclear (Obara et al., 2018), especially regarding gastrointestinal motor function.

The role of GI motility is the key to understanding the pathophysiology of symptoms related to the side effects of drugs and their prevention and management as well (Camilleri, Linden, 2016). Thus, our work aimed to evaluate the effects of cisplatin and dexamethasone alone or combined on the gastric contractility and morphometric of BALB/c and C57BL/6 mouse strains.

MATERIAL AND METHODS

Animals

Mouse strains were obtained from the Matrices Animal Facility at the University of São Paulo - USP. BALB/c (weighing 25‐30 g; n = 28) and C57BL/6 (weighing 18-22 g; n = 28) male mice aged 7-8-week-old were used in this study. The mice were kept in an enriched environment, individually housed in home cages under controlled conditions of temperature (22±2° C), humidity (60±5%), and 12-hour light/dark cycle with free access to standard laboratory chow pellets (Purina^®, Brazil) and filtered water before the experiments (Gama et al., 2020).

All experimental procedures were approved by the Ethics Committee on the Use of Animals of the Bioscience Institute of São Paulo State University - UNESP (protocol number 776) according to the Guidelines for Ethical Conduct in the Care and Use of Experimental Animals, and reported using the ARRIVE criteria.

Surgical procedures

After fasting for at least 6 hours, all the animals were anesthetized intraperitoneally (IP) with 85 mg/Kg ketamine (Cetamin^®, Syntec, Brazil) and 8.5 mg/Kg xylazine (Xilazin^®, Syntec, Brazil) and submitted to a laparotomy. A magnetic marker (diameter 4.0 mm; height 1.0 mm) was fixed with cyanoacrylate glue in the seromuscular layer of the stomach, 4.0 mm away from the limiting ridge.

Experimental protocol

Seven days after surgical recovery, twenty-eight animals of each strain were randomly separated, by a computer-generated sequence, into four groups: a) Control - BALB/c (n=7) and C57BL/6 (n=7) which received an injection of the saline solution in a volume equal to drugs (0.3 mL); b) Cis - BALB/c (n=7) and C57BL/6 (n=7) which received an injection of 7.5 mg/Kg Cisplatin (Fauldcispla^® 10 mg, Libbs Farmacêutica Ltda, Brazil); c) Dex - BALB/c (n=7) and C57BL/6 (n=7) which received an injection of 2.0 mg/Kg dexamethasone (Decadron^®, Aché Laboratories, Brazil); and d) Dex+Cis- BALB/c (n=7) and C57BL/6 (n=7) which received an injection of 2.0 mg/Kg dexamethasone 1 hour before treatment with cisplatin (Malik et al., 2007; Yamamoto, Yamatodani, 2018). All the drugs and saline solution were administered intraperitoneally.

The body weight was evaluated daily throughout the three days of the experiment. Food intake (24-hour consumption) was assessed during the second day of treatment and normalized per gram body weight in all groups. Gastric contractility was evaluated in all groups BALB/c and C57BL/6 after the third dose of drugs or saline. Afterward, all the animals were killed by anesthetic overdose (300 mg/Kg ketamine plus 30 mg/Kg xylazine, IP). A laparotomy was performed to collect the stomach for morphological analysis. Figure 1 illustrates the timeline of the study protocol.

FIGURE 1
Experimental setup for the study protocol. Drugs or saline were administered once daily for three days. Food intake was assessed after the first 24h post drugs administration; contractility analysis and stomach collection for histology were performed after 3rd dose administration.

Gastric contractility measurements

Gastric contractility was evaluated using the Alternating Current Biosusceptometry (ACB) technique (Br4-Science^®, Brazil) (Américo et al., 2010).

Briefly, the ACB technique uses sensors that are an assembly of excitation and detection coils able to generate magnetic fields to detect the response from a magnetic marker. Contractility waves are detected as signals from the magnetic marker fixed in the seromuscular layer in response to a magnetic field applied by the sensor, according to the movement or distance of the animal’s abdominal surface in relation to the sensor. Detailed technical information was reported earlier (Corá et al., 2005; Américo et al., 2010).

For gastric contractility measurements, mice fasted for 12 hours, during which the animals had water ad libitum. After ingesting 250 mg of standard laboratory chow, BALB/c and C57BL/6 groups were anesthetized intraperitoneally with 75 mg/Kg ketamine (Cetamin^®, Syntec, Brazil) plus 2.5 mg/Kg acepromazine (Acepran^®, Vetnil, Brazil). The animals were then laid supine and the ACB sensor was placed on the stomach surface towards recording the magnetic signals continuously for 20 minutes at a sampling rate of 20 Hz, by using a multichannel recorder (MP100 System; BIOPAC, Santa Barbara, CA, USA) (Américo et al., 2010).

Signals from the gastric contractility data were blindly analyzed in MatLab^® (R2015a, Natick, MA, USA) by visual inspection and Fast Fourier Transform (FFT). The highest frequency peak for each FFT was determined as the dominant gastric frequency and the lowest was the intrinsic noise of the signal. Gastric frequencies were expressed as cycles per minute (cpm). The amplitude of contractions was determined by the ratio between the intensity of the gastric peak (P) and the noise peak intensity (P’) and was expressed in decibels (dB) as follows: A = 10 log₁₀ (P/P’) (Lu et al., 2005; Gama et al., 2020). Normogastria was defined as a range of frequencies with 2SD (standard deviation) of the gastric frequency obtained in the control groups. The average values that were below this frequency range were classified as bradygastria, whereas average values above were classified as tachygastria (Marques et al., 2014).

Gastric morphometry

As described earlier, animals were killed for tissue collection. Stomachs were removed and immersion-fixed for 24 h in 10% buffered formalin. From then on, tissues were embedded in paraffin to be cut into 4 mm-thick sections and stained with hematoxylin and eosin (HE). HE staining was used for morphometric analysis of the thickness of the gastric muscular and mucosa. The images were captured using an Eclipse E200-Nikon optical microscope (Nikon, Japan), in objective x10, equipped with a 5.0 MP digital camera system (model ISH 500, Opton, Brazil), connected to a computer, and with an image capture program (TCapture). Ten measurements for each structure (mucosa/muscular) per animal were made (Pini et al., 2016). All morphometric measurements were blindly analyzed using ImageJ software (NIH, USA).

Statistical analysis

Data normally distributed (according to the Shapiro‐Wilk test) were expressed as mean ± SD, and analyzed using one-way analysis of variance (ANOVA) followed by Dunnet’s test, only if F achieved p<0.05, and there was no significant variance in homogeneity. Morphometric analysis was presented as median ± range, and the statistical variation among groups was tested by Kruskal-Wallis’s test followed by Dunn’s test. Values of p<0.05 were considered statistically significant.

RESULTS

BALB/c and C57BL/6 mice did not show significant changes in body weight during treatment with cisplatin, dexamethasone, or with both drugs simultaneously (Figure 2A). Cisplatin reduced the relative food intake in BALB/c animals, but not in C57BL/6 (Figure 2B). Dexamethasone did not affect the relative food intake and body weight in BALB/c mice; when combined with cisplatin, it prevented the reduction in food intake caused by cisplatin alone. In C57BL/6 mice, dexamethasone alone or combined with cisplatin did not change the relative food intake.

FIGURE 2
Body weight (A) and Food intake relative normalized per gram body weight (B) in Control, Cis, Dex, and Dex+Cis groups in BALB/c and C57BL/6 mouse strains. *p < 0.05 vs Control group, indicate significant within-strain differences. The results are expressed as mean ± SD (n = 7). One-way ANOVA followed by Dunnet’s post hoc test.

Figure 3 depicts the signals from gastric contractility registered in BALB/c and C57BL/6 mouse strains and their respective FFT spectrum. Gastric contractility was evaluated through the frequency and amplitude of contractions.

FIGURE 3
Representatives of gastric contractility signals and their respective FFT spectrum obtained for Control, Cis, Dex, and Dex+Cis groups in BALB/c and C57BL/6 mouse strains.

In the BALB/c strain, the control group had a mean gastric frequency of 5.3 ± 0.5 cpm; normogastria was determined as frequencies ranging from 4.3 - 6.3 cpm. Similarly, in C57BL/6 mice, the control group had a mean gastric frequency of 5.4 ± 0.6 cpm; normogastria was determined as a range of frequencies between 4.2 - 6.6 cpm. Cisplatin reduced frequency of gastric contractions and caused bradygastria only in BALB/c (Figure 4A). Dexamethasone had no effect on the frequency of gastric contractions in BALB/c, but combined with cisplatin, prevented bradygastria caused by cisplatin. In C57BL/6 mice, the frequency of gastric contractions was not affected by any of the drugs administered isolated or in the combination.

FIGURE 4
Frequency (A) and amplitude (B) of gastric contractions in Control, Cis, Dex, and Dex+Cis groups quantified for both BALB/c and C57BL/6 strains. *p < 0.05 vs Control group, indicate significant within-strain differences. The results are expressed as mean ± SD (n = 7). One-way ANOVA followed by Dunnet’s post hoc test.

Cisplatin reduced the amplitude of gastric contractions in both BALB/ and C57BL/6 (Figure 4B). Dexamethasone increased gastric amplitude only in BALB/c. Dexamethasone combined with cisplatin was not able to reverse the reduction in gastric amplitude caused by cisplatin on both mouse strains.

Regarding the morphometric analysis, the thickness of the gastric mucosa was not affected by cisplatin alone or in association with dexamethasone for both strains (Figure 5A). Dexamethasone alone did not affect gastric mucosa thickness in BALB/c, but increased the mucosa thickness in C57BL/6. Cisplatin alone did not affect the thickness of the gastric muscular in BALB/c and C57LB/6 mice (Figure 5B). Dexamethasone administered alone decreased the gastric muscle layer in BALB/c; however, when combined with cisplatin, this effect does not exist. Gastric muscular thickness in C57BL/6 was not affected by dexamethasone alone or combined with cisplatin.

FIGURE 5
Histomorphometry of gastric mucosa and muscular and in Control, Cis, Dex and Dex+Cis groups in BALB/c and C57BL/6 mouse strains are shown at the top of the panel. Representative photomicrographs of HE stained sections of stomachs of BALB/c and C57BL/6 mouse strains are shown at the bottom of the panel (original magnification ×10). *p < 0.05 vs Control group, indicate significant within-strain differences. The results are expressed as median ± range (n=7). Kruskal-Wallis’s test followed by the Dunn’s test.

DISCUSSION

Our study showed that the administration of cisplatin and dexamethasone alone or in association results in disturbed gastric contractility and morphometric alterations in BALB/c and C57BL/6 mouse strains. These findings reinforce that the appropriate mouse strain is vitally important for safety and dose translation to clinical studies.

In our BALB/c and C57BL/6 mice, there were no significant changes in body weight after administration of cisplatin, as well as reported in previous studies (Aston et al., 2017; Yamamoto, Yamatodani, 2018). Cisplatin alone reduced the relative food intake in the BALB/c but did not affect C57BL/6 strain. Studies showed that cisplatin reduced food intake in C57BL/6 mice dose-dependently, whereas it remained constant in BALB/c (Liu et al., 2005; Holland et al., 2014; Yamamoto, Yamatodani, 2018). Dexamethasone combined with cisplatin avoids food intake reduction in BALB/c mice. It has already been demonstrated that Dexamethasone is able to inhibit cisplatin-induced anorexia in DBA mouse strain (Yamamoto, Yamatodani, 2018).

Although symptoms such as nausea and vomiting are often related to gastric disorders, the mechanisms triggered by drugs are not fully understood (Pini et al., 2016). Changes in gastric motility entail changes in frequency and/or in amplitude of contractions (Jin et al., 2020). Our data depicted that gastric frequency and amplitude were similar for both strains at the baseline, but BALB/c and C57BL/6 respond differently to the drugs administered. Cisplatin decreased the frequency of gastric contractions and caused a bradygastric pattern only in the BALB/c strain. The amplitude of contractions, in turn, was decreased in both BALB/c and C57BL/6 mice. Similarly, studies performed in rats treated with cisplatin reported decreases in the frequency of slow waves associated with a delay of gastric emptying, as well as decreases in the frequency and amplitude of gastric contractions (Gong et al., 2016; Liu et al., 2018; Guo et al., 2019). Shortened amplitude peaks from the slow wave imply reduced voltage-dependent activation of Ca²⁺ influx into smooth muscle cells, with consequent diminished contractile activity (Izbeki et al., 2010).

Acute or chronic cisplatin administration in rats may be associated with gastric dysmotility and other symptoms related to decreased meal ingestion (Cabezos et al., 2008). Our results showed a decrease in food intake parallels to bradygastria and decreased amplitude in BALB/c treated with cisplatin. In C57BL/6, only the amplitude of contractions was reduced by cisplatin. It is important to highlight that food intake and gastric contractility was evaluated in an acute phase -response and it is possible that the C57BL/6 response to cisplatin is delayed, denoting a limitation of this study.

Regarding the morphometric analysis, cisplatin alone or in combination with dexamethasone did not affect the thickness of the gastric mucosa and muscle layers in both strains. Indeed, cisplatin causes damage to the gastrointestinal mucosa along the whole gastrointestinal tract in a dose and time-dependent manner (Perše, 2021). The absence of morphometric alterations in our study may be related to the short time of the experimental protocol. A previous study showed that 4 weeks of treatment with cisplatin resulted in gastric distension and neuropathy besides a significant decrease in the thickness of gastric mucosa in C57BL/6 mice (Pini et al., 2016).

It is important to underline the range of adverse effects associated with corticosteroids in the GI tract even when used as an antiemetic, as this may correlated with the symptoms (Vardy et al., 2006). Our data pointed out that dexamethasone combined with cisplatin prevented bradygastric and, consequently, the decrease of food intake in BALB/c mice. Similarly, the administration of dexamethasone to cisplatin-treated rats inhibited pica, improved food intake, and reduced the weight of gastric content (Rudd et al., 2002; Malik et al., 2007; Obara et al., 2018). This effect may be connected to the inhibition of the production of inflammatory mediators (Plata-Salamán, 1991; Obara et al., 2018) and also to the increased transmembrane Ca²⁺ influx in smooth muscle cells generated for glucocorticoids, as seen in vascular smooth muscle in rabbits (Kornel et al., 1995). Conversely, the decrease in gastric amplitude of contractions was not prevented by the combination of dexamethasone and cisplatin in both BALB/c and C57BL/6 mice, suggesting that this gastric variable seems to be disturbed by different pathways in acute treatment.

Studies focused on gastrointestinal toxicity induced by cisplatin or on the investigation of gastroprotective strategies are scant (Shahid, Farooqui, Khan, 2018). Similarly, there are few studies underline on gastric function in mice presumably due to model or methodology limitations. Conflicting results regarding the effects of drugs may be a result of differences in dose, route and period of treatment, and animal model as well. It seems worthwhile noting that a study into 17 different mouse genomes, including classical laboratory strains and the progenitors of strains linked to over 5000 different types of knockout mice, identified 56.7 million unique single-nucleotide polymorphisms, 8.8 million unique indels and 0.28 million structural variants (Keane et al., 2011). Acute administration of cisplatin alone seems to lead to fewer changes on C57BL/6. In the study of Aston et al. (2017), the effects of dexamethasone combined with cisplatin showed a dose-dependent profile on weight loss, where the optimum dosage of dexamethasone is up to 0.2 mg/kg to avoid loss of body mass. In this study, the gastrointestinal tract was not evaluated. In our study, the dose of dexamethasone used was 2.0 mg/kg according to Malik et al. (2007), which demonstrated effects on the stomach. Dosage adopted may have contributed to the increase in the thickness of the gastric mucosa in C57BL/6 and the reduced thickness of the gastric muscle in BALB/c.

In terms of side effect of drugs on gastrointestinal function, the ACB technique proved to be suitable to evaluate the differences in the duodenal contractility, and gastrointestinal transit between BALB/c and C57BL/6 mouse strains (Gama et al., 2020). Nevertheless, the mechanisms contributing to differences in the physiology of the stomach between BALB/c and C57BL/6 mice require further study.

BALB/c and C57BL/6 mice showed a similar baseline, but the acute effect of cisplatin and dexamethasone alone or combined on the food intake, gastric morphometry and contractility were influenced by the strain. In conclusion, our results reinforce the importance of choosing the appropriate mouse strain for studying the acute effects of anticancer and protective drugs on the gastrointestinal tract.

ACKNOWLEDGMENTS

This work was supported by funding from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) [Finance Code 001].

REFERENCES

• Américo MF, Marques RG, Zandoná EA, Andreis U, Stelzer M, Corá LA, et al. Validation of ACB in vitro and in vivo as a biomagnetic method for measuring stomach contraction. Neurogastroenterol Motil. 2010;22(12):1340-e374.
• Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017;17(1):1-10.
• Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci. 2008;141(1-2):54-65.
• Camilleri M, Linden DR. Measurement of gastrointestinal and colonic motor functions in humans and animals. Cell Mol Gastroenterol Hepatol. 2016;2(4):412-28.
• Clements PJ, Bolon B, McInnes E, Mukaratirwa S, Scudamore C. Animal Models in Toxicologic Research: Rodents, Haschek WM, Rousseaux CG, Wallig AM, Bolon B, Haschek and Rousseaux’s Handbook of Toxicologic Pathology (Fourth Edition). Academic Press. 2021,653-94.
• Corá LA, Romeiro FG, Stelzer M, Américo M, Oliveira RB, Baffa O, et al. AC Biosusceptometry in the study of drug delivery. Adv Drug Deliv Rev. 2005;57(8):1223-41.
• Gama LA, Machado MPR, Beckmann APS, Miranda JRA, Corá LA, Américo MF. Gastrointestinal motility and morphology in mice: Strain‐dependent differences. Neurogastroenterol Motil . 2020;32(6):e13824.
• Gong D, Zhao H, Liang Y, Chao R, Chen L, Yang S, et al. Differences in cocaine-and morphine-induced cognitive impairments and serum corticosterone between C57BL/6J and BALB/cJ mice. Pharmacol Biochem Behav. 2019;182:1-6.
• Gong YL, Liu F, Jin H, Xu L, Guo FF. Involvement of ghrelin in nucleus tractus solitaries on gastric signal afferent and gastric motility in cisplatin-treated rats. Eur Rev Med Pharmacol Sci. 2016;20(16):3480-89.
• Gosselin T, Le Guisquet AM, Brizard B, Hommet C, Minier F, Belzung C. Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice. Behav Pharmacol. 2017;28(6):466-476.
• Guo F, Xu L, Gao S, Sun X, Zhang N, Gong Y. Effect of orexin-A in the arcuate nucleus on cisplatin-induced gastric side effects in rats. Neurosci Res. 2019;143:53-60.
• Holland RA, Leonard JJ, Kensey NA, Hannikainen PA, De Jonghe BC. Cisplatin induces neuronal activation and increases central AMPA and NMDA receptor subunit gene expression in mice. Physiol Behav. 2014;136:79-85.
• Izbeki F, Asuzu DT, Lorincz A, Bardskey MR, Popko LN, Choi KN, et al. Loss of Kitlow progenitors, reduced stem cell factor and high oxidative stress underlie gastric dysfunction in progeric mice. J Physiol. 2010;588(16):3101-17.
• Jin T, Jiang Z, Luan X, Qu Z, Guo F, Gao S, et al. Exogenous orexin-a microinjected into central nucleus of the amygdala modulates feeding and gastric motility in rats. Front Neurosci. 2020;14:274.
• Keane T, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature. 2011;477(7364):289-94.
• Kornel L, Prancan AV, Kanamarlapudi N, Hynes J, Kuzianik E. Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo. Endocr Res. 1995;21(1-2):203-210.
• Liu Y, Zhang S, Ye F, Yin J, Li S, Chen JD. Ameliorating effects and mechanisms of chronic electroacupuncture at ST36 in a rodent model of dyspepsia induced by cisplatin. Neurogastroenterol Motil . 2018;31(1):e13474.
• Liu YL, Malik N, Sanger GJ, Friedman MI, Andrews PL. Pica - a model of nausea? Species differences in response to cisplatin. Physiol Behav . 2005;85(3):271-7.
• Lu CL, Chen CY, Luo JC, Chang FY, Lee SD, Wu HC, et al. Impaired gastric myoelectricity in patients with chronic pancreatitis: Role of maldigestion. World J Gastroenterol. 2005;11(3):372-6.
• Malik NM, Liu YL, Cole N, Sanger GJ, Andrews PL. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur J Pharmacol. 2007;555(2-3):164-73.
• Marques RG, Américo MF, Spadella CT, Corá LA, Oliveira RB, Miranda JRA. Different patterns between mechanical and electrical activities: an approach to investigate gastric motility in a model of long-term diabetic rats. Physiol Meas. 2014;35(1):69-81.
• Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005;288(6):G1328-38.
• Miller KE, Bajzer Ž, Hein SS, Phillips JE, Syed S, Wright AM, et al. High temporal resolution gastric emptying breath tests in mice. Neurogastroenterol Motil. 2018;30(8):e13333.
• Natale JJ. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Hosp Pract (1995). 2015;43(4):226-34.
• Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356-67.
• Obara Y, Machida T, Takano Y, Shiga A, Suzuzi A, Hamaue N, et al. Cisplatin increases the number of enterochromaffin cells containing substance P in rat intestine. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(8):847-858.
• Perše M. Cisplatin mouse models: treatment, toxicity and translatability. Biomedicines. 2021;9(10):1406.
• Pini A, Garella R, Idrizaj E, Calosi L, Baccari MC, Vannucchi MG. Glucagon‐like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus. Neurogastroenterol Motil. 2016;28(2):206-16.
• Plata-Salamán CR. Dexamethasone inhibits food intake suppression induced by low doses of interleukin-1 β administered intracerebroventricularly. Brain Res Bull. 1991;27(5):737-8.
• Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32(8):1469-86.
• Rudd JA, Yamamoto K, Yamatodani A, Takeda N. Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption (“pica”) in rats. Eur J Pharmacol . 2002;454(1):47-52.
• Sanger GJ, Broad J, Andrews PL. The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. Eur J Pharmacol . 2013;715(1-3):10-4.
• Sankoorikal GM, Kaercher KA, Boon CJ, Lee JK, Brodkin ES. A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry. 2006;59(5):415-23.
• Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol . 2018;827:49-57.
• Soni KG, Halder T, Conner ME, Preidis GA. Sexual dimorphism in upper gastrointestinal motility is dependent on duration of fast, time of day, age, and strain of mice. Neurogastroenterol Motil . 2019;31(9):e13654.
• Uranga JA, García‐Martínez JM, García‐Jiménez C, Vera G, Martín‐Fontelles MI, Abalo R. Alterations in the small intestinal wall and motor function after repeated cisplatin in rat. Neurogastroenterol Motil . 2017;29(7):e13047.
• Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94(7):1011-5.
• Viana-Cardoso KV, da Silva MT, Palheta Júnior RC, Peixoto Junior AA, Pinho LG, Santos AA, et al. Repeated cisplatin treatments inhibit gastrointestinal motility and induces baroreflex changes and mechanical hyperalgesia in rats. Cancer Invest. 2011;29(7):494-500.
• Yamamoto K, Okui R, Yamatodani A. Effects of a histamine H4 receptor antagonist on cisplatin-induced anorexia in mice. Neurosci Lett. 2018;676:103-107.
• Yamamoto K, Yamatodani A. Strain differences in the development of cisplatin-induced pica behavior in mice. J Pharmacol Toxicol Methods. 2018;91:66-71.
• Yang CK, Wu CE, Liaw CC. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy. Biomed J. 2016;39(1):60-6.

Publication Dates

• Publication in this collection
  28 Aug 2023
• Date of issue
  2023

History

• Received
  27 Sept 2022
• Accepted
  24 May 2023